DK1355566T3 - Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ - Google Patents

Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ

Info

Publication number
DK1355566T3
DK1355566T3 DK01991306.0T DK01991306T DK1355566T3 DK 1355566 T3 DK1355566 T3 DK 1355566T3 DK 01991306 T DK01991306 T DK 01991306T DK 1355566 T3 DK1355566 T3 DK 1355566T3
Authority
DK
Denmark
Prior art keywords
radiotherapy
hydrogel
situ
local regional
regional chemotherapy
Prior art date
Application number
DK01991306.0T
Other languages
English (en)
Inventor
David J Yang
Ali Azhdarinia
Tommy L Lee
Edmund E Kim
Dong-Fang Yu
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK1355566T3 publication Critical patent/DK1355566T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK01991306.0T 2000-12-18 2001-12-18 Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ DK1355566T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25651400P 2000-12-18 2000-12-18
PCT/US2001/049087 WO2002049501A2 (en) 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using in situ hydrogel

Publications (1)

Publication Number Publication Date
DK1355566T3 true DK1355566T3 (da) 2013-03-04

Family

ID=22972510

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01991306.0T DK1355566T3 (da) 2000-12-18 2001-12-18 Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ

Country Status (8)

Country Link
US (2) US7008633B2 (da)
EP (1) EP1355566B1 (da)
JP (1) JP2004528278A (da)
AU (1) AU3104102A (da)
CA (1) CA2432797C (da)
DK (1) DK1355566T3 (da)
HK (1) HK1060283A1 (da)
WO (1) WO2002049501A2 (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7008633B2 (en) * 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8758820B2 (en) 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
EP1670449B1 (en) 2003-09-15 2012-06-27 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use in angiogenesis
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20120143167A1 (en) * 2004-04-16 2012-06-07 Morrison Dennis R Methods For Improved Cryo-Chemotherapy Tissue Ablation
US7833187B2 (en) * 2004-04-16 2010-11-16 Nuvue Therapeutics, Inc. Systems and methods for improving image-guided tissue ablation
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
WO2006108324A1 (fr) * 2005-04-15 2006-10-19 Beijing Shengyiyao Science & Technology Development Co., Ltd Suppositoire vasculaire microsphérique contenant des composés pharmaceutiques gynécologiques d’alginate de sodium et sa méthode de préparation
WO2007011674A2 (en) * 2005-07-15 2007-01-25 Baker Donald J Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20080260771A1 (en) * 2006-09-12 2008-10-23 Olalde Rangel Jose A Prostate disorder(s) phyto-nutraceutical synergistic composition
US20080199546A1 (en) * 2006-10-24 2008-08-21 Krempin David W Anti-resorptive and bone building dietary supplements and methods of use
ES2535005T3 (es) 2006-12-22 2015-05-04 Nanopharmaceuticals Llc Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
US7850382B2 (en) * 2007-01-18 2010-12-14 Sanford, L.P. Valve made from two materials and writing utensil with retractable tip incorporating same
US7488130B2 (en) * 2007-02-01 2009-02-10 Sanford, L.P. Seal assembly for retractable instrument
US8226312B2 (en) * 2008-03-28 2012-07-24 Sanford, L.P. Valve door having a force directing component and retractable instruments comprising same
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
PL2274422T3 (pl) * 2008-04-17 2017-09-29 Anaeropharma Science, Inc. Wektor ekspresyjny
JP2010104694A (ja) 2008-10-31 2010-05-13 Mitsubishi Heavy Ind Ltd 補助人工心臓の異常検出装置、補助人工心臓の異常検出方法、及び異常検出プログラム
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US8221012B2 (en) * 2008-11-07 2012-07-17 Sanford, L.P. Retractable instruments comprising a one-piece valve door actuating assembly
CA2745383A1 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
US20100135945A1 (en) * 2008-12-02 2010-06-03 Kreations By Kristin, Llc Gymnema-containing lip balm compositions and associated methods
CH702736B1 (de) * 2008-12-31 2012-12-14 Obschestvo S Organichennoi Otvetstvennostju Scient Company Flamena Phospholipid-Emulsion, die Dihydroquerzetin beinhaltet.
US8393814B2 (en) 2009-01-30 2013-03-12 Sanford, L.P. Retractable instrument having a two stage protraction/retraction sequence
WO2010098652A1 (en) * 2009-02-24 2010-09-02 Universiti Putra Malaysia Cola nitida ( cola nut ) as an anticancer agent
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8663210B2 (en) * 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
EP2442800B1 (en) 2009-06-17 2019-04-24 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
AU2010269074B9 (en) 2009-07-09 2016-11-24 Swinburne University Of Technology Biopolymer hybrid gel-depot delivery system
US7897184B1 (en) * 2009-08-13 2011-03-01 Access Business Group International Llc Topical composition with skin lightening effect
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
ES2650226T3 (es) 2009-12-01 2018-01-17 Bridgestone Corporation Composiciones de caucho modificadas y métodos de preparación
KR101850162B1 (ko) * 2010-01-29 2018-04-18 가부시키가이샤 아네로파마·사이엔스 형질전환용 플라스미드
US9504643B2 (en) * 2010-03-29 2016-11-29 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
CN102462664A (zh) * 2010-11-18 2012-05-23 华侨大学 一种磺酸基巯基壳聚糖介入栓塞化疗缓释微球及其制备方法
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
WO2013006821A1 (en) * 2011-07-07 2013-01-10 Research Cancer Institute Of America Systems, methods, and formulations for treating cancer
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
HUE057423T2 (hu) 2012-01-12 2022-05-28 Endo Global Ventures Clostridium histolyticum enzim
US9480747B2 (en) 2012-01-24 2016-11-01 Bvw Holding Ag Class of anti-adhesion hydrogels with healing aspects
TWI503132B (zh) * 2012-04-27 2015-10-11 Univ Nat Cheng Kung 栓塞用醫藥微粒
NL2009688C2 (en) * 2012-10-24 2014-04-29 Nucletron Operations Bv A settable radioactive gel, a method of manufacturing a settable radioactive gel, a device for manufacturing a settable radioactive gel.
US20140194370A1 (en) 2013-01-08 2014-07-10 University Of Utah Research Foundation Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer
CN103157129B (zh) * 2013-03-13 2014-10-01 上海大学 用于骨修复的聚氨基酸/羟基磷灰石复合水凝胶及其制备方法
EP3034091A1 (en) 2013-03-15 2016-06-22 BioSpecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
ITRM20130312A1 (it) * 2013-05-29 2014-11-30 Aboca Spa Societa Agricola Estratto di cynara spp. e suoi usi.
TWM467462U (zh) * 2013-06-05 2013-12-11 Chin-Tung Lee 幾丁質修飾乙醇微脂載體結構
ES2807907T3 (es) * 2013-08-13 2021-02-24 Natreon Inc Extracto de Terminalia bellerica para la inhibición de xantina oxidasa y disminución de ácido úrico en suero
CN103751102A (zh) * 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
CN104950005A (zh) * 2014-03-26 2015-09-30 中国科学院大连化学物理研究所 区分淡干和盐干海参及涨发海参含水量的定性分析方法
CN105647825B (zh) * 2014-11-13 2019-05-21 中国科学院大连化学物理研究所 一种同时提高螺旋藻生物质和多糖产率的方法
WO2016103190A1 (en) 2014-12-24 2016-06-30 The University Of North Carolina At Chapel Hill Combined local delivery of therapeutic agents using interventional devices and radiation
CN104698021B (zh) * 2015-01-22 2017-01-18 天津中医药大学 一种黄芪注射液初生代谢成分的含量检测方法
US20180289809A1 (en) * 2015-01-22 2018-10-11 Bcs Business Consulting Services Pte Ltd. Formulations of hydrophilic compounds
US9919016B2 (en) * 2015-02-10 2018-03-20 Bilal Qizilbash Product and method of deploying kale derivatives for anti-cancer effects
US20180353613A1 (en) * 2015-05-05 2018-12-13 B.G. Negev Technologies And Applications Ltd Anionic nanoparticles for use in the delivery of anionic small molecule drugs
US10905783B2 (en) 2015-11-27 2021-02-02 Michal RIVLIN Glucosamine and derivatives thereof in imaging
CN109715551A (zh) 2016-06-07 2019-05-03 纳米药业有限责任公司 与αvβ3整联蛋白甲状腺拮抗剂缀合的不可裂解聚合物
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
CN106834682A (zh) * 2017-01-20 2017-06-13 卜琰 一种硫酸锌溶液中萃锗除氯的方法
CA3055041A1 (en) 2017-03-01 2018-09-07 Endo Ventures Limited Apparatus and method for assessing and treating cellulite
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
BR112019020394A2 (pt) 2017-03-28 2020-04-22 Endo Ventures Ltd método melhorado de produção de colagenase
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
CN107213479B (zh) 2017-06-22 2018-12-28 苏州杰纳生物科技有限公司 一种包含过氧化氢酶的组合物及用途
CN107375939B (zh) * 2017-07-19 2021-02-23 中国药科大学 用于治疗真菌感染的两性霉素b多肽类水凝胶载药体系
EP3501553A1 (en) * 2017-12-21 2019-06-26 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Hydrogel comprising manganese, methods and uses thereof
US11446348B2 (en) 2017-12-30 2022-09-20 Bilal Qizilbash Vegetable powders, methods for manufacturing vegetable powders, and kits thereof
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
CN109758675A (zh) * 2019-01-29 2019-05-17 青岛中腾生物技术有限公司 一种自愈合医用凝胶
US20220288001A1 (en) * 2019-09-25 2022-09-15 The Regents Of The University Of California Creatine for immunotherapy
WO2021076618A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN111557968A (zh) * 2020-03-17 2020-08-21 常州市中医医院 一种具有调节免疫功能的中药复方组合物与应用
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
CN112457857A (zh) * 2020-10-31 2021-03-09 兰州资源环境职业技术学院 一种去除煤矿区重金属的土壤改良剂
WO2023055963A1 (en) 2021-09-29 2023-04-06 Boston Scientific Scimed, Inc. Injectable shear-thinning hydrogel containing therapetuic agent for enhanced tumor therapy
NO347755B1 (en) * 2021-10-21 2024-03-18 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides
CN114224823B (zh) * 2021-11-02 2023-12-05 南京医科大学 一种集化疗/光动力治疗/化学动力治疗“三位一体”的脑胶质瘤递药***及其制备方法
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
CN115970046B (zh) * 2022-12-02 2024-04-26 南京工业大学 一种多功能水凝胶在制备治疗糖尿病伤口药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1190855A (en) * 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
WO1986007600A1 (en) * 1985-06-19 1986-12-31 Exxon Chemical Patents Inc. Thermoplastic elastomer composition
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5257970A (en) 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
AU693821B2 (en) * 1993-11-18 1998-07-09 Sirtex Medical Limited Controlled release preparation
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6074663A (en) * 1995-01-16 2000-06-13 Baxter International Inc. Method of using cross-linked fibrin material
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
CN1213316A (zh) * 1996-03-11 1999-04-07 富克尔公司 放射性核素及放射性医药品的聚合物输送
EP1683520B1 (en) * 1996-03-12 2013-11-20 PG-TXL Company, L.P. Water-soluble prodrugs
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
JP4116683B2 (ja) 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 徐放性局所送達製剤
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6146373A (en) * 1997-10-17 2000-11-14 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent
AU754003B2 (en) 1998-06-30 2002-10-31 Amgen, Inc. Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US7008633B2 (en) * 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel

Also Published As

Publication number Publication date
EP1355566A2 (en) 2003-10-29
WO2002049501A2 (en) 2002-06-27
EP1355566A4 (en) 2007-10-24
WO2002049501A3 (en) 2003-09-04
AU3104102A (en) 2002-07-01
EP1355566B1 (en) 2012-11-28
US7008633B2 (en) 2006-03-07
HK1060283A1 (en) 2004-08-06
US20050208138A1 (en) 2005-09-22
CA2432797C (en) 2014-02-04
US20050227910A1 (en) 2005-10-13
CA2432797A1 (en) 2002-06-27
JP2004528278A (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
DK1355566T3 (da) Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
NO20025018L (no) Selektiv hydroprosessering og merkaptanfjerning
NO20014553L (no) Bronnplanlegging og konstruksjon
FI20010080A (fi) Autentikointi tietoliikenteessä
DK1339292T3 (da) Sammensætning og fremgangsmåde
NO20013745D0 (no) Ventiler for bruk i brönner
FI19991949A (fi) Suljettu käyttäjäryhmäpalvelu matkaviestinjärjestelmässä
DK1263745T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiaxol-2-oner og anvendelse deraf til inhibering af hormonfölsom lipase
NO992839L (no) Sikkerhetsfunksjon i mobilt nettverk
NO20004355L (no) Retarderende systemer og anvendelse derav ved oljebronnsementering
DK1441746T3 (da) Sammens tning og fremgangsmode
NO20021087L (no) Hengslet deksel til bruk i veier o.l.
FI981311A (fi) Matkaviestimen kuljetuspakkaus
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
DK1317478T3 (da) Skelnen mellem GnRH-I og GnRH-II
FI20012229A (fi) Kiinnitysjärjestely matkaviestimessä
NO20025135D0 (no) Antihypertensive midler og anvendelse
ATE474032T1 (de) Fischer-tropsch-verfahren
ATE235724T1 (de) Zugangsberechtigungs-buchungsverfahren
DK1139532T3 (da) Fordelingstavle og rammelement
NO20022179L (no) Glidebestandig og absorberende materiale
FI20002858A (fi) Autentikointi tietoliikenteessä
DK1240373T3 (da) Bånd og fremgangsmåde til fremstilling af dette
NO20003213D0 (no) FremgangsmÕte og element for bygging med glassbygger-sten
SE0001847D0 (sv) Mobil visa